Plasma concentration of neuropeptide Y in patients with adrenal hypertension

Abstract

The mechanisms of hypertension during primary hyperaldosteronism and Cushing's syndrome are not completely understood. An enhanced vascular sensitivity to noradrenaline has been described in both situations. Neuropeptide Y (NPY) induces direct vasoconstriction and potentiates the action of noradrenaline. Sodium retention and dexamethasone have been shown to increase circulating NPY levels in animals and the expression of NPY in neuroendocrine cells. In order to determine if NPY could be involved in the enhanced vascular sensitivity to noradrenaline associated with adrenocortical hyperactivity, we measured plasma NPY in patients with Cushing's syndrome ( n = 26) and primary hyperaldosteronism ( n = 15) and compared it with that of hypertensive patients with pheochromocytomas ( n = 13) or essential hypertension ( n = 51) and with normotensive controls ( n = 47). The concentration of NPY-Like immunoreactivity (NPY-Li) (mean ± S.E.) in controls was 39.6 ± 3.0 pg/ml . Elevated concentrations were found in 77% of the samples collected from pheochromocytoma patients ( 1180.4 ± 394.0 pg/ml ). NPY-Li levels in patients with essential hypertension ( 35.0 ± 2.6 pg/ml ), primary hyperaldosteronism ( 31.3 ± 3.9 pg/ml ) and Cushing's syndrome ( 33.1 ± 4.8 pg/ml ) were not different from that of controls. NPY-Li levels in hypertensive and normotensive patients with Cushing's syndrome were similar ( 38.5 ± 7.5 vs 24.2 ± 3.7 pg/ml ). No correlation was found between the NPY-Li level and the mean blood pressure at the time of sampling. Our results suggest that NPY is unlikely to be involved in the pathogenesis of hypertension associated with primary hyperaldosteronism and Cushing's syndrome.